Tag: Business
Biotech News Roundup: Stay Updated on the Latest Developments in the Industry
Good morning, everyone! Today, we have some interesting updates from the biotech industry. The BIOSECURE Act is facing a crucial moment as it needs to be passed by Congress by December to avoid obstacles,...
Pfizer’s New R&D Head, VC Deep-Dive, and FDA Commissioner: What You Need to Know
Pfizer has welcomed a new R&D head, Chris Boshoff, who is expected to make significant strides in research and development to satisfy investors. Additionally, the biotech venture capital landscape is set to see some...
FAQs: Understanding IGAs in Animals
Intentional Genomic Alterations (IGAs) in animals refer to changes made to an animal's DNA using modern molecular technologies. These alterations can include targeted DNA sequence changes like insertions, substitutions, or deletions, among others. Common...
Kura Oncology Licenses Leukemia Drug to Japanese Drugmaker
Kura Oncology and the Japanese drugmaker Kyowa Kirin have joined forces in a global partnership to work on Kura’s new treatment for acute leukemia. The drug, ziftomenib, is currently in a late-stage clinical trial...
Apellis Triumphs while Astellas Faces Defeat
Good morning! Today, there is a lot of news from the American Heart Association's annual meeting, and former National Cancer Institute chief Ned Sharpless has launched a new biotech company called Jupiter.
Here's what you...
Merck Drug Trial and Wegovy in China: Pharmalittle News Update
Good day to you! The Pharmalot team is here, ready to dive into the latest news in the pharmaceutical world. Today, we have some interesting updates to share with you, so grab a cup...
Navigating the Corporate Ladder: Recent Movements and Trends
In the world of corporate movements and trends, it's always exciting to hear about new hires, promotions, and other changes within companies. If you have any news to share about someone new joining your...
Pharmalittle: GSK Leaves BIO, AbbVie Schizophrenia Drug Fails & More – Pharma News Update
Good morning, everyone, and welcome to a new week of work. We hope you had a restful weekend and are ready to dive back into the routine of online meetings and deadlines. Let's start...
Ending 23andMe’s Drug Discovery Dream: What Went Wrong?
23andMe, the genetics company that many people have been excited about, recently made a big announcement. The company has decided to stop working on creating new medicines and will be letting go of 40%...
GSK Withdraws from BIO, Signaling Major Setback for Lobbying Group
Pharmaceutical company GSK has announced its decision to leave the Biotechnology Innovation Organization (BIO), which is the largest trade group in the biotechnology industry. This move by GSK marks a significant setback for the...
Biotech Outlook Post-Trump Presidency: What’s Next?
Adam: Hey Matt, glad you could join me today. The future of the biotech industry post-Trump presidency is something that many are curious about. One key aspect that everyone is keeping an eye on...
Sutter Health CEO Donates to Harris in Wake of Antitrust Investigation
Sutter Health's CEO, Warner Thomas, recently made significant donations to Vice President Harris' presidential campaign and the Democratic National Committee. Despite Harris' involvement in an antitrust investigation against Sutter Health in the past, Thomas...
















